Cargando…

Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model

GRID directs alternating regions of high- and low-dose radiation at tumors. A large animal model mimicking the geometries of human treatments is needed to complement existing rodent systems (eg, microbeam) and clarify the physical and biological attributes of GRID. A pilot study was undertaken in pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Michael W., Gieger, Tracy L., Karakashian, Alexander A., Nikolova-Karakashian, Mariana N., Posner, Lysa P., Roback, Donald M., Rivera, Judith N., Chang, Sha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616052/
https://www.ncbi.nlm.nih.gov/pubmed/28168937
http://dx.doi.org/10.1177/1533034617690980
_version_ 1783266716189458432
author Nolan, Michael W.
Gieger, Tracy L.
Karakashian, Alexander A.
Nikolova-Karakashian, Mariana N.
Posner, Lysa P.
Roback, Donald M.
Rivera, Judith N.
Chang, Sha
author_facet Nolan, Michael W.
Gieger, Tracy L.
Karakashian, Alexander A.
Nikolova-Karakashian, Mariana N.
Posner, Lysa P.
Roback, Donald M.
Rivera, Judith N.
Chang, Sha
author_sort Nolan, Michael W.
collection PubMed
description GRID directs alternating regions of high- and low-dose radiation at tumors. A large animal model mimicking the geometries of human treatments is needed to complement existing rodent systems (eg, microbeam) and clarify the physical and biological attributes of GRID. A pilot study was undertaken in pet dogs with spontaneous soft tissue sarcomas to characterize responses to GRID. Subjects were treated with either 20 Gy (3 dogs) or 25 Gy (3 dogs), delivered using 6 MV X-rays and a commercial GRID collimator. Acute toxicity and tumor responses were assessed 2, 4, and 6 weeks later. Acute Radiation Therapy Oncology Group grade I skin toxicity was observed in 3 of the 6 dogs; none experienced a measurable response, per Response Evaluation Criteria in Solid Tumors. Serum vascular endothelial growth factor, tumor necrosis factor α, and secretory sphingomyelinase were assayed at baseline, 1, 4, 24, and 48 hours after treatment. There was a trend toward platelet-corrected serum vascular endothelial growth factor concentration being lower 1 and 48 hours after GRID than at baseline. There was a significant decrease in secretory sphingomyelinase activity 48 hours after 25 Gy GRID (P = .03). Serum tumor necrosis factor α was quantified measurable at baseline in 4 of the 6 dogs and decreased in each of those subjects at all post-GRID time points. The new information generated by this study includes the observation that high-dose, single fraction application of GRID does not induce measurable reduction in volume of canine soft tissue sarcomas. In contrast to previously published data, these data suggest that GRID may be associated with at least short-term reduction in serum concentration of vascular endothelial growth factor and serum activity of secretory sphingomyelinase. Because GRID can be applied safely, and these tumors can be subsequently surgically resected as part of routine veterinary care, pet dogs with sarcomas are an appealing model for studying the radiobiologic responses to spatially fractionated radiotherapy.
format Online
Article
Text
id pubmed-5616052
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-56160522017-10-03 Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model Nolan, Michael W. Gieger, Tracy L. Karakashian, Alexander A. Nikolova-Karakashian, Mariana N. Posner, Lysa P. Roback, Donald M. Rivera, Judith N. Chang, Sha Technol Cancer Res Treat Articles GRID directs alternating regions of high- and low-dose radiation at tumors. A large animal model mimicking the geometries of human treatments is needed to complement existing rodent systems (eg, microbeam) and clarify the physical and biological attributes of GRID. A pilot study was undertaken in pet dogs with spontaneous soft tissue sarcomas to characterize responses to GRID. Subjects were treated with either 20 Gy (3 dogs) or 25 Gy (3 dogs), delivered using 6 MV X-rays and a commercial GRID collimator. Acute toxicity and tumor responses were assessed 2, 4, and 6 weeks later. Acute Radiation Therapy Oncology Group grade I skin toxicity was observed in 3 of the 6 dogs; none experienced a measurable response, per Response Evaluation Criteria in Solid Tumors. Serum vascular endothelial growth factor, tumor necrosis factor α, and secretory sphingomyelinase were assayed at baseline, 1, 4, 24, and 48 hours after treatment. There was a trend toward platelet-corrected serum vascular endothelial growth factor concentration being lower 1 and 48 hours after GRID than at baseline. There was a significant decrease in secretory sphingomyelinase activity 48 hours after 25 Gy GRID (P = .03). Serum tumor necrosis factor α was quantified measurable at baseline in 4 of the 6 dogs and decreased in each of those subjects at all post-GRID time points. The new information generated by this study includes the observation that high-dose, single fraction application of GRID does not induce measurable reduction in volume of canine soft tissue sarcomas. In contrast to previously published data, these data suggest that GRID may be associated with at least short-term reduction in serum concentration of vascular endothelial growth factor and serum activity of secretory sphingomyelinase. Because GRID can be applied safely, and these tumors can be subsequently surgically resected as part of routine veterinary care, pet dogs with sarcomas are an appealing model for studying the radiobiologic responses to spatially fractionated radiotherapy. SAGE Publications 2017-02-07 2017-06 /pmc/articles/PMC5616052/ /pubmed/28168937 http://dx.doi.org/10.1177/1533034617690980 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Articles
Nolan, Michael W.
Gieger, Tracy L.
Karakashian, Alexander A.
Nikolova-Karakashian, Mariana N.
Posner, Lysa P.
Roback, Donald M.
Rivera, Judith N.
Chang, Sha
Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title_full Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title_fullStr Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title_full_unstemmed Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title_short Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model
title_sort outcomes of spatially fractionated radiotherapy (grid) for bulky soft tissue sarcomas in a large animal model
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616052/
https://www.ncbi.nlm.nih.gov/pubmed/28168937
http://dx.doi.org/10.1177/1533034617690980
work_keys_str_mv AT nolanmichaelw outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT giegertracyl outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT karakashianalexandera outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT nikolovakarakashianmarianan outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT posnerlysap outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT robackdonaldm outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT riverajudithn outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel
AT changsha outcomesofspatiallyfractionatedradiotherapygridforbulkysofttissuesarcomasinalargeanimalmodel